Mitsubishi Tanabe Pharma Canada (MTP-CA) Mitsubishi Tanabe Pharma Canada (MTP-CA) - Mobile
  • Français
  • Home
  • About Us
  • Science
  • Our People
  • Media Center
  • Contact Us
  • Resources
  • Careers
  • Global Site

You are now leaving Mitsubishi Tanabe Pharma Canada and visiting a third-party website.

Cancel Continue

If you are interested in exploring careers at MTP-CA, please email
contact@mt-pharma-canada.com.

Close
  • Mitsubishi Tanabe Pharma Canada Announces prRADICAVA® (Edaravone) Oral Suspension Is Now Available in Canada for the Treatment of Patients with ALS

  • prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from CADTH for the Treatment of Patients with ALS

  • prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from INESSS for the Treatment of Patients With ALS

  • Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of prRADICAVA® (Edaravone) Oral Suspension for the Treatment of Patients with ALS

  • Mitsubishi Tanabe Pharma Canada Announces Publication of Real-World Data for Radicava® (Edaravone)

  • Health Canada Accepts SNDS Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS

  • Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary

  • Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Is Now Available Through Newfoundland and Labrador Prescription Drug Program

  • MTP-CA Applauds the Release of Canada’s First ALS Management Guidelines

  • Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) Now Eligible for Coverage Through Veterans Affairs Canada and Indigenous Services Canada

Mitsubishi Tanabe Pharma Canada (MTP-CA)
OUR COMPANY
  • About Us
  • Science
  • Our People
RESOURCES
  • Medical Inquiries
MEDIA
  • Media Center
CONNECT WITH US
  • Global Site
  • Contact Us
  • Careers
  • Terms of Use
  • Compliance
  • Privacy Policy
© Mitsubishi Tanabe Pharma Canada (MTP-CA) 2023      CNP-CA-0001 06/20